Skip to content

Category: In the News

The Washington Post – The Pandemic Is Waning. Anthony Fauci Has a Few More Lessons to Share.

You gotta f—ing suck it up,” Anthony Fauci tells me from the deck of his home in Washington, D.C., overlooking a small pool that takes up nearly the entire backyard. The secret to his obscene productivity, he says, is to simply never stop working — even when “it’s 9 o’clock at night and you really,…

HealthLeaders Media – By Reducing Barriers, DCTs Improve Patient Access to Oncology Trials

The 2022 ASCO meeting kicked off in the first week in June, inspiring many discussions throughout the following weeks about new and exciting innovations in cancer care and treatment, but two buzzworthy topics included the need for more focus on diversity in cancer clinical trials and how sponsors can use the decentralized model to improve…

Medscape – FDA Okays Cancer Drugs Faster Than EMA. But at What Cost?

Over the past decade, the US Food and Drug Administration (FDA) has approved new cancer drugs twice as fast as the European Medicines Agency (EMA), often using accelerated pathways, a new analysis shows. Between 2010 and 2019, the FDA approved almost all oncology therapies ahead of the EMA. Drugs entered the US market about 8…

Springer Link – Patient, Family Member and Physician Perspectives and Experiences with AML Treatment Decision-Making

Introduction Acute myeloid leukemia (AML) is one of the more common blood cancers, characterized by peripheral blood and bone marrow myeloblast proliferation, leading to bone marrow failure and rapid death without treatment. AML primarily affects older adults, with a median age of almost 70 years [1, 2]. Previous research indicates that older patients with AML have substantial…

Regulatory Focus – This Week at FDA: User fee moves, COVID vaccine updates, and more

Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical device regulation and what we’re reading from around the web. There was a lot going on this week on the COVID-19 vaccines front. We made it through the first of several…

Fred Hutch – ASCO 2022: Equity, innovation and in-person

Cancer clinical trials have long had a disparity problem, but a new push for more equitable trials that are both diverse and open to patients with certain health conditions seems to be finally paying off, per new research released at the 2022 annual meeting of the American Society of Clinical Oncology, or ASCO. Fred Hutchinson Cancer…

The Fayetteville Observer – Fayetteville Observer’s 40 Under 40 Class of 2022: Brittany Avin McKelvey

Name: Brittany Avin McKelvey Age: 29 Birthplace/where you were raised: I was born in Camden, South Carolina, and grew up in Greenville, North Carolina. Where do you live now? Fayetteville Employer: Friends of Cancer Research Job title: I am a science policy analyst at Friends of Cancer Research (Friends). Friends is an advocacy organization based in Washington, D.C., that drives collaboration…

EurekAlert! – New drug combination lengthened survival for some with lung cancer

A study conducted under the Lung Cancer Master Protocol (Lung-MAP) found that patients with advanced non-small cell lung cancer whose cancer had progressed on previous immunotherapy lived significantly longer when treated with a combination of ramucirumab (Cyramza®) plus pembrolizumab (Keytruda®) than when treated with one of the current standard therapies for this type of cancer.…

Pink Sheet – Alzheimer’s Evidence Accelerator Modeled On FDA COVID Project Floated By USAgainstAlzheimer’s

UsAgainstAlzheimer’s wants to replicate the successful multi-stakeholder COVID-19 Evidence Accelerator led by the Reagan-Udall Foundation of the US Food and Drug Administration and Friends of Cancer Research with a similar effort focused on treating Alzheimer’s disease. The patient advocacy group released a request for information on developing an Alzheimer’s Disease Evidence Accelerator on 10 May and hopes…

AJMC – Dr Randall A. Oyer: Clinical Trials Must Be Accessible to Everyone

The theme for this year’s American Society of Clinical Oncology (ASCO) Annual Meeting is “Advancing Equitable Cancer Care Through Innovation,” and in this interview, Randall A. Oyer, MD, medical director, oncology, and medical director, Cancer Risk Evaluation Program, Lancaster General Health, and clinical professor of cancer biology at Penn Medicine, discusses the recent ASCO/Association of…